BIOSPECIA

Content Available at www.uniquepubinternational.com
(An International online peer reviewed Journal) ISSN (O): 3139-2091

Review Article

OPEN ACCESS

FROM RISK TO QUALITY: QUALITY RISK MANAGEMENT IN PHARMA

CHILAKA MERIMMA*, SREYA, CH. LAKSHMI, CHANDU BABU RAO

Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

Article History: Received: 24 Mar 2026, Revised: 19 Apr 2026, Accepted: 18 May 2026

***Corresponding author**
Chilaka Merimma

Abstract

According to the International Council for Harmonization's (ICH) Q9 (R1) guideline, which goes into effect in May 2023, Quality Risk Management (QRM) offers a systematic and scientific method for controlling risks to the quality of pharmaceutical products at every stage of their lifetime. In order to increase uniformity within quality systems, the updated advice places a strong emphasis on risk-based decision-making, suitable formality levels, and the elimination of subjectivity. By helping pharmaceutical companies to recognize, evaluate, control, communicate, and analyse risks that might affect product safety, effectiveness, and compliance, QRM works closely with quality assurance. This study emphasizes the function of risk assessments in the production, distribution, and regulatory contexts of pharmaceuticals, showing how methodical assessment aids in avoiding quality failures and maximizing resource use. Numerous risk management techniques and instruments are covered, along with their usefulness, advantages, as well as restrictions. In order to improve proactive risk management, the study also examines implementation issues and new developments including digital technology, data analytics, and predictive methodologies.

Keywords: *Risk assessment, best practices, QRM tools, QRM methodology, quality risk management, and product safety.*

1. INTRODUCTION

QRM is a systematic method for managing, analyzing, testing, evaluating, and assessing (clinical) risks associated with the pharmaceutical product's quality during the course of its lifespan. A QRM example figure is shown. Other models could be helpful as well. Other models could also be useful. Although the importance of each structural element might vary depending on the topic, a robust process requires taking into account each aspect both separately and in connection with the others [1]. QRM is a systematic process for recognizing, controlling, sharing, and evaluating risks that may affect the quality of pharmaceutical (medicinal) goods throughout their lifespan. The flowchart illustrates a framework for Rims. An outstanding framework for applying risk management in pharmaceutical product development is offered by the International Conference on Harmonization (ICH) Q9-quality risk management (QRM). The flowchart shows the model for Rims. Q9: Quality Risk Management (QRM) at the International Conference on Harmonization (ICH).

2. SCOPE OF QUALITY RISK MANAGEMENT

This project used to fix known problems or to implement continuous quality improvements. These requirements apply to all new and existing GMP areas and operations, process methods, resources, equipment and procedures [2]. These functions include development, production and sales, lifetime inspection and shipping /testing processes for pharmaceuticals (including raw materials, solvent displays, packaging and labeling products).

Principle

The ideas of fine danger control are: Assessing danger for fine need to be primarily based totally on medical know-how and in the long run connected to affected person safety; And The effort, technique and high satisfactory of the High satisfactory hazards control method must be associated with the extent the hazards. In addition, the pharmaceutical enterprise and regulates can examine and controlled hazards the use of authorized hazard control gear and/or inner procedure (e. g, fashionable working producers) below is whole listing oaf few gear. Basic risk management facilitation methods; FMEA (Failure Mode Effect Analysis). FMECA (Failure Modes, Effect and Criticality Analysis); FTA (Fault Tree Analysis); HACCP (Hazard Analysis and Critical Control Point); HAZOP (Hazard Function Analysis); PHA (Preliminary Hazard Analysis) [3].

Process of Quality Risk Management

1. Initiating QRM process: The initiating phase of QRM process involves understanding the risk event by defining and agreeing the context, the scope, and the tolerability criteria for the QRM, together with any underlying assumptions. It should involve all the stakeholders; all the relevant information is assembled and shared.

2. Quality risk assessment: Quality risk assessment is a systematic process of organizing information to support a risk decision Tube made within a risk management process. It consists of the identification of hazards and the analysis and evaluation of risks associated with exposure to those hazards. [4-8]

3. Risk control: It includes decision-making to reduce and/or accept risks. Its purpose is to reduce the risk to an acceptable level. Decision makers might use different processes, including benefit-cost analysis, for understanding the optimal level of risk control. The steps for risk control include: a) Risk reduction: Risk reduction includes actions taken to lessen the probability of the occurrence of harm and severity of that harm usually by corrective action and preventive action and change control's

4. Risk communication: It is the sharing of information about risk and risk management between the decision makers and others. Parties can communicate at any stage of the risk management process. The output/result of the QRM process should be appropriately communicated and documented.

5. Risk review: It should be an ongoing part of the quality management process. A mechanism to review or monitor events should be implemented. The output/results of the risk management process should be reviewed to take into account new knowledge and experience.

3. RISK ASSESSMENT

Risk assessment includes of the identified trouble; the hazards of the analysis and the assessment of the risk related with manifestation to the hazards. The pharmaceutical industry is organized and complex, with a focus on producing drugs that are safe, effective, and of high quality. Quality assurance and risk management are the two critical components of the pharmaceutical industry that are essential for ensuring patient safety and product quality.

3.1 Types of Risk Assessment

Failure Mode Effect Analysis

FEMA is utilized in form of industries, for hazard control purposes, wherein the identity of hazard known as parameters, and easy quantification of hazardous insufficient. FEMA became delivered with inside the Forties for navy use with the aid of using the US. Industry with inside the US followed Failure Mode Effect Analysis in the Seventies in element due to commercial failures together with the chemical plant ignition in fibrous UK, in 1974 FMEA method is a scientific technique to pick out capacity disasters to satisfy supposed function, to pick out feasible failure reasons so the reasons may be removed, and to discover the effects of disasters so the results may be reduced.

4. REGULATORY GUID LINES

Quality Risk Management (QRM) in the pharmaceutical industry does not operate in isolation; it is guided by a set of well-established regulatory frameworks and standards that ensure consistency, reliability, and global harmonization. These guidelines provide a structured approach to identifying, assessing, and mitigating risks, and they emphasize the importance of integrating risk-based thinking into every aspect of the product lifecycle.

1. ICH Q9: Quality Risk Management

The International Council for Harmonization (ICH) introduced the Q9 guideline in 2005, marking a major step toward standardizing risk management practices in the pharmaceutical sector. ICH Q9 outlines a systematic process for QRM, emphasizing that risk-based decisions should be science based, documented, and transparent.

Key principles of ICH Q9 include

- Risk Identification: Recognizing potential hazards that could affect product quality or patient safety.
- Risk Assessment: Evaluating the likelihood and severity of each identified risk.
- Risk Control: Implementing measures to mitigate or eliminate risks.
- Risk Communication: Sharing risk information with relevant stakeholders.
- Risk Review: Continuously monitoring and updating risk assessments as new data or knowledge becomes available.

ICH Q9 encourages organizations to adopt flexible, proportional approaches focusing resources on the most critical areas while avoiding unnecessary controls for low impact risks. It also emphasizes that QRM should be a dynamic process, applied throughout the product lifecycle, from development through manufacturing to post market surveillance.

2. FDA Guidance on Quality Risk Management (QRM)

The United States Food and Drug Administration (FDA) strongly promotes the implementation of Quality Risk Management (QRM) as a fundamental component of modern pharmaceutical quality systems. QRM is a systematic process used to assess, control, communicate, and review risks to product quality throughout the product lifecycle. The FDA's risk-based approach to Good Manufacturing Practice (GMP) compliance encourages pharmaceutical manufacturers to adopt scientific and structured risk management strategies to ensure patient safety, product efficacy, and regulatory compliance.

Risk-Based Approach in GMP Compliance

FDA guidance emphasizes that risk management should be embedded within all stages of pharmaceutical manufacturing, including development, technology transfer, commercial production, and post-market monitoring. Rather than applying uniform regulatory oversight to every process, the FDA encourages companies to identify critical risks and allocate resources where they have the greatest impact on product quality. This risk-based philosophy allows manufacturers to focus on high-risk processes, critical quality attributes (CQAs), and critical process parameters (CPPs), thereby improving efficiency while maintaining strict safety standards.

Benefits of FDA-Aligned QRM Practices

Implementing FDA-aligned QRM practices provides several operational and regulatory advantages. Firstly, it enhances product quality and patient safety by identifying potential failures early in the manufacturing process. Secondly, it supports efficient resource utilization by focusing efforts on high-risk areas rather than applying unnecessary controls across all activities. Thirdly, risk-based decision-making encourages innovation and flexibility, allowing companies to adopt new technologies or process improvements with confidence.

From a regulatory perspective, companies that maintain robust QRM systems are better prepared for inspections and submissions. Risk-based justifications can support reduced testing strategies, flexible validation approaches, and streamlined regulatory communication. Ultimately, the adoption of QRM fosters a culture of continuous improvement where data-driven decisions lead to sustainable quality performance Risk assessment tools such as Failure Mode and Effects Analysis (FMEA), Hazard Analysis and Critical Control Points (HACCP), and risk ranking methods are commonly recommended to evaluate potential hazards. These tools help identify sources of variability, potential contamination risks, equipment failures, or process deviations that could affect the final product. By implementing structured assessments, organizations can prioritize corrective actions and establish preventive controls before problems occur.

5. TOOLS OF QUALITY RISK MANAGEMENT

From a regulatory perspective, companies that maintain robust QRM systems are better prepared for inspections and submissions. Risk-based justifications can support reduced testing strategies, flexible validation approaches, and streamlined regulatory communication. Ultimately, the adoption of QRM fosters a culture of continuous improvement where data-driven decisions lead to sustainable quality performance [9].

6. APPLICATIONS OF QUALITY RISK MANAGEMENT [10].

sophisticated equipment, and stringent regulatory standards. Even minor deviations in process parameters or product quality can have serious consequences for patient safety, product efficacy, and regulatory compliance.

1. Quality Control (QC): One of the most critical applications of QRM is in quality control, where it helps ensure that products meet predefined standards. QRM enables QC teams to:

Focus on Critical Quality Attributes (CQAs): These include potency, purity, dissolution, stability, and microbial limits. By identifying which attributes have the highest impact on product quality and patient safety, QC teams can prioritize their monitoring efforts

2. Supply Chain Management: Modern pharmaceutical supply chains are increasingly global and complex. Raw materials, excipients, and intermediates may come from multiple vendors, each with its own variability. QRM helps organizations identify and mitigate supply chain risks, such as:

Raw Material Variability: Differences in raw material quality can impact product potency, stability, or safety.

7. CHALLENGES AND IMPLEMENTATION OF QUALITY RISK MANAGEMENT (QRM)

Despite the significant advantages offered by Quality Risk Management (QRM), its practical implementation within pharmaceutical manufacturing environments presents several organizational, technical, and operational challenges. As regulatory expectations continue to evolve and manufacturing processes become more complex, companies must address these barriers to fully realize the benefits of a risk-based quality system.

8. FUTURE PERSPECTIVES OF QUALITY RISK MANAGEMENT

The pharmaceutical industry is undergoing a significant transformation driven by technological innovation, increasing regulatory expectations, and the complexity of modern therapies. As risks in manufacturing, clinical trials, and supply chains become more sophisticated, the future of Quality Risk Management (QRM) lies in adopting proactive, intelligent, and globally aligned approaches. Below is an in depth look at emerging trends and perspectives shaping the future of QRM.

1. Digital Integration and Artificial Intelligence (AI)

The integration of digital technologies, artificial intelligence (AI), and machine learning is set to revolutionize QRM. Traditionally, risk assessment relied on manual data analysis, historical experience, and periodic reviews. Now, digital tools allow organizations to:

Predict Potential Failures: AI algorithms can analyse vast amounts of process, equipment, and environmental data to identify subtle patterns indicating potential failures. For example, in tablet manufacturing, deviations in compression force or powder flow can be detected before they affect product quality [11].

Recommend Preventive Actions: Machine learning models can suggest interventions, such as adjusting equipment parameters or triggering maintenance schedules, ensuring proactive risk mitigation. Enhance Decision Making: Advanced analytics provide insights that go beyond human observation, helping organizations prioritize high impact risks and allocate resources more effectively. By adopting digital and AI driven QRM, pharmaceutical companies can move from reactive problem solving to predictive, data driven risk management, improving efficiency, reducing errors, and enhancing patient safety.

9. CONCLUSION

Well-accessed methodology structured to find current quality risk assessment, that is, ICH Q9 guideline. Here above in this paper given number of applications and risk management tools. It is a process consisting of evaluation, control, and review of the risk emerging out for quality. The common risk management tools used in application of risk tithe quality are risk ranking, FMEA, and HACCP. The first step is to identify appropriate risk methodology subsequent to the risk. The severity of the risk is taken into account. QRM provides better ability to handle the risk pertaining in the quality of product throughout its lifecycle. In conclusion, this review article has explored the important relationship between quality assurance and risk management in the pharmaceutical industry. We have discussed how risk assessments are used to identify and mitigate potential quality issues, and explored some of the best practices for implementing effective risk management strategies. Overall, it is clear that quality assurance and risk management are critical areas of focus for pharmaceutical companies, as they can help ensure that products are safe and effective for patients, and can help companies meet regulatory requirements and maintain a competitive edge in the marketplace. In terms of future research or initiatives, there are several areas that could be explored further. For example, researchers could investigate new technologies or methodologies for conducting risk assessments, or could explore how risk management strategies could be applied in new areas of the pharmaceutical industry, such as gene therapy or personalized medicine. Quality Risk Management (QRM) has emerged as a cornerstone of modern pharmaceutical practice, playing a vital role in safeguarding patient safety, ensuring product quality, and maintaining regulatory compliance. In today's highly complex and tightly regulated environment, even minor deviations in manufacturing, formulation, or supply chain processes can have significant consequences. QRM provides a structured, science based, and proactive framework to identify, assess, and control such risks before they escalate into serious problems. By systematically evaluating potential failures, organizations can prioritize critical risks based on their likelihood, severity, and detectability. This ensures that resources are allocated efficiently, addressing the most significant threats to product quality and patient safety while monitoring lower risk areas appropriately. For example, identifying potential contamination in sterile manufacturing early allows preventive interventions, rather than costly recalls or regulatory penalties later.

10. AUTHOR CONTRIBUTIONS

All authors are contributed equally.

11. FINANCIAL SUPPORT

None

12. DECLARTION COMPETING INTEREST

The authors have no conflicts of interest to declare.

13. ACKNOWLEDGEMENTS

NONE

14. REFERENCES

1. Hardwicke CJ. The World Health Organization and the pharmaceutical industry: common areas of interest and differing views. Adverse Drug React Toxicol Rev. 2002;21(1):51-99.
2. International Council for Harmonisation. ICH Q9(R1): Quality risk management. Geneva: ICH; 2023.
3. International Council for Harmonisation. ICH Q9: Quality risk management. Geneva: ICH; 2005.
4. Osha A, Bhargava S. International council for harmonization (ICH) guidelines. In: Regulatory Affairs in the Pharmaceutical Industry. Academic Press; 2022. p. 47-74.
5. Lazore PL. International Cooperation, Convergence and Harmonization of Pharmaceutical Regulations: A Global Perspective. Academic Press; 2013.
6. Code of Federal Regulations. Hazard analysis and critical control point (HACCP) systems. CFR Title 21 Part 120. United States; 2001.
7. Hwisa NT, Gindi S, Rao CB, Katakam P, Rao Chandu B. Evaluation of antiulcer activity of Picrasma quassioides Bennett aqueous extract in rodents. Vedic Res Int Phytomedicine. 2013;1:27-32.
8. Gindi S, Methra T, Rao Chandu B, et al. Antiurolithiatic and in vitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J Pharm Pharm Sci. 2013;2(2):636-649.
9. Nama S, Chandu BR, et al. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Trop J Pharm Res. 2011;10(4):489-495.
10. Kiranmai R, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Res Pharm Chem. 2012;2(2):636-649.
11. Rao AA, Rao CHB, Devanna N. Design and evaluation of mucoadhesive buccal bilayered tablets of metoprolol succinate. World J Pharm Res. 2017;7(3):172-178.
12. Sreekanth N, Awen BZ, Rao BC. Development and validation of new analytical methods for the estimation of capecitabine in pharmaceutical dosage form. Res J Pharm Biol Chem Sci. 2010;1(2):39-46.